In today’s briefing:
- Episode 107: NVIDIA Earnings and Peak Nvidia? (Sentiment Wise)
- META: The Last of the Mohicans Standing – A Buy Opportunity
- BBW: 4Q Preview: Evolution Continues; Reiterate Buy, $58 PT
- QNRX: More Positive Data Supporting Efficacy of QRX003 for NS Campaign to Raise Awareness of the Disease
- ThredUp, Inc. – Strong Momentum from 4Q Continues

Episode 107: NVIDIA Earnings and Peak Nvidia? (Sentiment Wise)
- Nvidia’s stock has underperformed this year due to intense scrutiny and high expectations
- Despite strong fundamentals, it is difficult for Nvidia to surprise investors and move the stock price
- Potential for upside lies in Blackwell demand and upcoming announcements, but meaningful surprises may be limited due to the company’s high level of scrutiny and public knowledge
This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only.
META: The Last of the Mohicans Standing – A Buy Opportunity
- All but one of the Magnificent 7 stocks have seen their rallies collapse, breaking their long-term uptrends. The lone exception? Meta Platforms (META US).
- Mark Zuckerberg’s company is the only Magnificent 7 stock that has pulled back yet may still be holding its uptrend intact.
- Our model has identified a tactical BUY opportunity in the support price area around 640. Keep reading for the details…
BBW: 4Q Preview: Evolution Continues; Reiterate Buy, $58 PT
- We are reiterating our Buy rating, $58 price target and projections for Build-A-Bear Workshop, with the company announcing 4QFY24 (January) results on Wednesday before the open.
- We believe, with impressive owned store results during the Holidays and the new third party locations becoming an increasingly higher piece of the overall profitability of the business, Build-A-Berar is poised for strong 4Q results and potential top and bottom line upside.
- Further, with the company enjoying a strong Valentine’s Day season and the Spring calendar materially more favorable, we believe management will be positive for FY25.
QNRX: More Positive Data Supporting Efficacy of QRX003 for NS Campaign to Raise Awareness of the Disease
- There are no approved NS treatments currently & Quoin is optimistic that QRX003 can become the first.
- The overall patient population is fairly sizable QNRX estimates there are ~6k-7k patients in the U.S. and EU.
- Moreover, NS is often undiagnosed.
ThredUp, Inc. – Strong Momentum from 4Q Continues
- 4Q results and 2025 outlook were already discussed, hence there were no surprises.
- The key takeaways from the call and callbacks include the following.
- Strong pickup in new buyers in 4Q, with momentum continuing into 1Q25.
